Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis
Brief Summary: This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days. In addition to an optimized background regimen (OBR), participants will be randomized to receive:

* 100 mg OPC-67683 twice daily (BID)
* 200 mg OPC-67683 BID
* Placebo BID

After 56 days participants will complete their optimized background regimen (OBR).


Options:
A: Arm Label: Regimen 1 - 2EHRZ/4HR (control regimen); Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 2 - 2MHRZ/2MHR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 3 - 2EMRZ/2MR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Intervention Type: DRUG; Name: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin; Assigned to Arm(s): Regimen 1 - 2EHRZ/4HR (control regimen), Regimen 2 - 2MHRZ/2MHR, Regimen 3 - 2EMRZ/2MR
B: Arm Label: Delamanid 100 mg BID + OBR; Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Optimized Background Regimen (OBR), Drug: Placebo | Arm Label: Delamanid 200 mg BID + OBR; Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Optimized Background Regimen (OBR) | Arm Label: Placebo + OBR; Type: PLACEBO_COMPARATOR; Interventions: Drug: Optimized Background Regimen (OBR), Drug: Placebo | Intervention Type: DRUG; Name: Delamanid; Assigned to Arm(s): Delamanid 100 mg BID + OBR, Delamanid 200 mg BID + OBR | Intervention Type: DRUG; Name: Optimized Background Regimen (OBR); Assigned to Arm(s): Delamanid 100 mg BID + OBR, Delamanid 200 mg BID + OBR, Placebo + OBR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Delamanid 100 mg BID + OBR, Placebo + OBR
C: Arm Label: experimental group1; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol, Drug: Levofloxacin | Arm Label: experimental group2; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Arm Label: Control regimen group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Rifampicin; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Ethambutol; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): experimental group1
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 5; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 6 (optional); Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Linezolid Cohort; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid Cohort

Answer: B